StockNews.AI
INCY
StockNews.AI
62 days

Incyte Announces FDA Approval of Monjuvi® (tafasitamab-cxix) in Combination with Rituximab and Lenalidomide for Patients with Relapsed or Refractory Follicular Lymphoma

1. INCY's Monjuvi® approved by FDA for relapsed FL treatment. 2. Approval enhances treatment options for patients and market position.

FDA Approval
-0.04%Current Return
VS
-0.05%S&P 500
$68.29506/18 03:51 PM EDTEvent Start
$68.2706/19 10:07 PM EDTLatest Updated
2m saved
Insight
Article

FAQ

Why Bullish?

FDA approval could lead to increased patient adoption and revenue growth, similar to past drug approvals in oncology that have driven stock price up significantly.

How important is it?

The article presents a significant FDA approval that can materially affect INCY's market stance and revenue from increased drug use.

Why Short Term?

Immediate market reactions to FDA approvals typically drive short-term stock price movements, evidenced by previous FDA drug launch timelines impacting similar biotech firms.

Related Companies

RHHBYPFEBMY
WILMINGTON, Del.--(BUSINESS WIRE)--Incyte (Nasdaq:INCY) today announced that the U.S. Food and Drug Administration (FDA) has approved Monjuvi® (tafasitamab-cxix), a humanized Fc-modified cytolytic CD19-targeting monoclonal antibody, in combination with rituximab and lenalidomide for the treatment of adult patients with relapsed or refractory follicular lymphoma (FL). "Patients living with relapsed or refractory FL have been waiting for new options that improve progression-free survival without.

Related News